Moberg Pharma AB Interim report January - June 2021
REGISTRATION PREPARATIONS FULLY UNDERWAYSIX-MONTH PERIOD (JAN-JUN 2021) · EBITDA SEK -8.9 million (-9.3) * · Operating profit (EBIT) SEK -10.2 million (-10.5)* · Profit after tax SEK -8.3 million (-8.6) * · Total profit SEK 15.3 million (-8,6) ** · Diluted earnings per share SEK 0.36 (-0.46) ** · Cash and cash equivalents amounted to SEK 124.2 million (43.0) SECOND QUARTER (APR-JUN 2021) · EBITDA SEK -3.5 million (-5.7) * · Operating profit (EBIT) SEK -4.1 million (-6.3)* · Profit after tax SEK -3.3 million (-5.2) * · Total profit SEK -3.3 million (-5.2)